INSYS Therapeutics, Inc. (INSY) Analysts See $-0.32 EPS

September 30, 2018 - By Jack Shaw

Investors sentiment increased to 1.33 in 2018 Q2. Its up 0.58, from 0.75 in 2018Q1. It increased, as 13 investors sold INSYS Therapeutics, Inc. shares while 17 reduced holdings. 14 funds opened positions while 26 raised stakes. 12.52 million shares or 0.87% more from 12.41 million shares in 2018Q1 were reported.
Citigroup Incorporated stated it has 3,067 shares or 0% of all its holdings. California Pub Employees Retirement Sys holds 75,500 shares. Bluemountain Capital Management Ltd Liability Corp has 4,442 shares. State Bank Of America Corporation De, North Carolina-based fund reported 8,415 shares. Moreover, Great West Life Assurance Company Can has 0% invested in INSYS Therapeutics, Inc. (NASDAQ:INSY). Moreover, Invesco Ltd has 0% invested in INSYS Therapeutics, Inc. (NASDAQ:INSY) for 33,696 shares. Manufacturers Life The reported 23,908 shares stake. National Bank & Trust Of Mellon Corp, New York-based fund reported 108,745 shares. Moreover, Winslow Evans And Crocker has 0.01% invested in INSYS Therapeutics, Inc. (NASDAQ:INSY). Credit Suisse Ag, a Switzerland-based fund reported 19,768 shares. Proshare Advsrs Limited Liability Company reported 34,561 shares. Raymond James And, Florida-based fund reported 18,483 shares. Principal Fincl Grp Inc invested 0% of its portfolio in INSYS Therapeutics, Inc. (NASDAQ:INSY). Moreover, Blackrock Inc has 0% invested in INSYS Therapeutics, Inc. (NASDAQ:INSY) for 2.64M shares. Geode Cap Mngmt Ltd Liability stated it has 301,748 shares.

Analysts expect INSYS Therapeutics, Inc. (NASDAQ:INSY) to report $-0.32 EPS on November, 1.They anticipate $0.07 EPS change or 28.00 % from last quarter’s $-0.25 EPS. After having $-0.37 EPS previously, INSYS Therapeutics, Inc.’s analysts see -13.51 % EPS growth. The stock increased 1.41% or $0.14 during the last trading session, reaching $10.08. About 522,979 shares traded. INSYS Therapeutics, Inc. (NASDAQ:INSY) has declined 6.48% since September 30, 2017 and is downtrending. It has underperformed by 22.10% the S&P500.

Insys Therapeutics, Inc., a specialty pharmaceutical company, develops and commercializes supportive care products. The company has market cap of $748.39 million. The firm markets SUBSYS, a sublingual fentanyl spray for breakthrough cancer pain in opioid-tolerant cancer patients in the United States. It currently has negative earnings. The Company’s lead product candidate is SYNDROS, an orally administered liquid formulation of dronabinol for treating CINV and anorexia associated with weight loss in patients with AIDS.

More notable recent INSYS Therapeutics, Inc. (NASDAQ:INSY) news were published by: Seekingalpha.com which released: “INSYS Therapeutics completes initial clinical study of dronabinol inhalation, shares up 3.7% premarket” on September 24, 2018, also Nasdaq.com with their article: “Marijuana Stock GW Pharmaceuticals Nabs DEA Schedule V” published on September 27, 2018, Fool.com published: “The Single Biggest Opportunity for Cannabis Stocks” on September 28, 2018. More interesting news about INSYS Therapeutics, Inc. (NASDAQ:INSY) were released by: Nasdaq.com and their article: “Here’s Why INSYS Therapeutics, Inc. Jumped a Whopping 40.3% in August” published on September 06, 2018 as well as Nasdaq.com‘s news article titled: “INSYS Therapeutics and UC San Diego’s Center for Medicinal Cannabis Research Expand Collaboration to Include …” with publication date: September 04, 2018.

INSYS Therapeutics, Inc. (NASDAQ:INSY) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: